Jamil Abou El Hossen Duarte, MD
Internal Medicine · Fajardo, PRNPI 1356347538
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,484 of the $11,697 with a category attached, or 89.6%. It is spread thinly across 25 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $2,380 and has fallen 56.7% since, to $1,030 in 2025. Among internal medicine clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 403 payments — averaging $29.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- E.r. Squibb & Sons, L.L.C.$2K
- Boehringer Ingelheim$1K
- Johnson & Johnson$1K
- Sanofi-aventis U.S. LLC$975
- Novo Nordisk$801
- plus $3K from 19 others
What the payments were for
- Consulting fees$1,14410%
- Food & beverage$10,48490%
- Education$691%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 104 | $2,479 |
| E.r. Squibb & Sons, L.L.C. | 17 | $1,518 |
| Boehringer Ingelheim | 40 | $1,287 |
| Johnson & Johnson | 46 | $1,280 |
| Sanofi-aventis U.S. LLC | 39 | $975 |
| Novo Nordisk | 35 | $801 |
| Eli Lilly Export S.A. Puerto Rico Branch | 27 | $654 |
| PBG Puerto Rico LLC | 20 | $467 |
| Merck | 17 | $398 |
| Amgen | 16 | $359 |
| GSK | 10 | $296 |
| AbbVie | 5 | $227 |
| Bayer | 1 | $125 |
| Shionogi Inc | 1 | $125 |
| Gilead | 1 | $122 |
| Bayer Puerto Rico Inc. | 5 | $117 |
| Boston Scientific | 1 | $90 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $75 |
| ANI Pharmaceuticals, Inc. | 3 | $75 |
| Pfizer Pharmaceuticals LLC | 4 | $68 |
| Lilly USA, LLC | 3 | $49 |
| Abbott | 2 | $36 |
| Exact Sciences | 1 | $25 |
| Novartis | 1 | $24 |
| Dexcom, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,697 in reported general payments places this provider in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Synjardy XrEmpagliflozin/Metformin Hcl | 264 | $259,210 |
| TrulicityDulaglutide | 191 | $216,293 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 259 | $202,600 |
| JardianceEmpagliflozin | 268 | $202,305 |
| FarxigaDapagliflozin Propanediol | 243 | $195,757 |
| EliquisApixaban | 210 | $169,764 |
| XareltoRivaroxaban | 202 | $159,956 |
| SynjardyEmpagliflozin/Metformin Hcl | 182 | $144,800 |
| LinzessLinaclotide | 146 | $106,345 |
| EntrestoSacubitril/Valsartan | 111 | $99,577 |
| GlyxambiEmpagliflozin/Linagliptin | 93 | $87,905 |
| MounjaroTirzepatide | 72 | $76,978 |
| TradjentaLinagliptin | 83 | $74,810 |
| JanuviaSitagliptin Phosphate | 82 | $74,249 |
| OzempicSemaglutide | 65 | $71,305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy Xr, Trijardy Xr, Jardiance, Synjardy, Glyxambi | $1,287 | $987,8001,172 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $49 | $293,271263 claims |
| AstraZenecaFarxiga, Brilinta, Lokelma | $2,479 | $231,815294 claims |
| MerckJanuvia, Janumet Xr, Janumet | $398 | $181,448220 claims |
| AbbVieLinzess, Synthroid | $227 | $170,952896 claims |
| Johnson & JohnsonXarelto | $1,280 | $159,956202 claims |
| NovartisEntresto | $24 | $99,577111 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $975 | $82,813285 claims |
| Novo NordiskOzempic, Rybelsus | $801 | $82,16976 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $296 | $23,45249 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $75 | $10,468380 claims |
| BayerKerendia | $125 | $8,04012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Other internal medicine in Fajardo
- Nelson VallejoLas Piedras$621K
- Ricardo FernandezSan Juan$351K
- Ronald Collazo PaganManati$206K
- Angel VinuelaDorado$182K
- Julio JimenezSan Lorenzo$99K
- Luis Negron GarciaSan German$24K
- Jorge Torres OlmedaCoto Laurel$23K
- Norma SalgadoSan Juan$21K
- Victor Gordo GonzalezSan Juan$21K
- Luis Rivera ColonRio Piedras$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.